Window Therapeutics is proud to be named an NCL awardee by the @National Cancer Institute’s Nanotechnology Characterization Laboratory. As an NCL awardee, our Antibody Brush-analogue macromolecule Conjugate (ABC) technology will undergo rigorous evaluation, bringing us closer to clinical trials and paving the way for a new era in cancer therapy.
For more information, see the NCL website here (https://www.cancer.gov/nano/research/ncl/about/collaborators)

Boston, MA and Bethesda, MD,
Window Therapeutics, Inc. (Window), a Massachusetts-based therapeutics company, today announced a foundational partnership and seed funding in collaboration with the National Foundation for Cancer Research (NFCR) through its AIM-HI Accelerator Fund (AIM-HI) biotechnology innovation award program. Terms of the seed-funding round were not disclosed.
Founded in 2020, Window is creating next-generation cancer therapeutics designed to overcome limited efficacy and prohibitive toxicity which often confound successful drug development and as well as favorable patient outcomes. The company’s revolutionary technology platform derives from research that began over ten years ago by Dr. Jeremiah Johnson at the Massachusetts Institute of Technology (MIT). Window’s Bottle-brush Analogue Macromolecule (BAM) platform modifies the therapeutic window of small molecule, immune-based, and combination drug treatments to maximize efficacy specifically within disease sites. AIM-HI identified Window, its technology, and lead drug programs as possessing significant potential for transforming cancer drug development and advancing promising targeted drugs and immunotherapeutic to the clinic in an accelerated manner. AIM-HI’s lead role in the seed-funding of Window is intended to catalyze the progression of its lead candidates to the clinic, based on BAM technology that alleviates the pharmacokinetics, bioavailability, and off-target effects that so often lead to drug candidate failure in clinical trials.
“The Window Therapeutics’ approach embodies our passion to urgently address the limitations of current cancer therapies,” said Sujuan Ba, Ph.D., co-Founder of AIM-HI and Chief Executive Officer of NFCR. “Our support for translating promising research from academia to the clinic by selectively identifying and nurturing early-stage companies accelerates treatment breakthroughs for cancer patients worldwide.”
“AIM-HI’s support in creating a path forward to the clinic for our novel, bottle-brush macromolecule-based drug programs to benefit cancer patients is truly transformational,” remarked Jeremiah Johnson, Ph.D., Window Therapeutics co-Founder, and Scientific Advisor. “Following a decade of progressive development to reconfigure drug therapeutic windows, we aspire to help clinicians and patients achieve and sustain successful outcomes.”

In March, 2020, Window Therapeutics in conjunction with the Johnson Lab at The Massachusetts Institute of Technology was awarded the prestigious Assay Cascade Grant, for its Window-Bortezomib program for Multiple Myeloma, from the Nanotechnology Characterization Laboratory (NCL), a division of the National Cancer Institute and the Frederick National Laboratory for Cancer Research. The NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program.
Nanomedicines accepted into the program undergo a rigorous evaluation ranging from sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are conducted free of charge for Awardees. Initiation of the evaluation of the Window-Bortezomib program began in the first half of 2021 with developmental research currently in progress.